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Survival rates of pediatric brain tumor patients have sig-
nificantly improved over the years due to developments 
in diagnostic techniques, neurosurgery, chemotherapy, 
radiotherapy, and supportive care. However, brain 
tumors are still an important cause of cancer-related 
deaths in children. Prognosis is still highly dependent 
on clinical characteristics, such as the age of the patient, 
tumor type, stage, and localization, but increased knowl-
edge about the genetic and biological features of these 
tumors is being obtained and might be useful to fur-
ther improve outcome for these patients. It has become 
clear that the deregulation of signaling pathways essen-
tial in brain development, for example, sonic hedgehog 
(SHH), Wnt, and Notch pathways, plays an important 
role in pathogenesis and biological behavior, especially 
for medulloblastomas. More recently, data have become 
available about the cells of origin of brain tumors and 
the possible existence of brain tumor stem cells. Newly 
developed array-based techniques for studying gene 
expression, protein expression, copy number aberrations, 
and epigenetic events have led to the identification of 
other potentially important biological abnormalities in 
pediatric medulloblastomas and ependymomas. Neuro-
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The causes of pediatric brain tumors are largely unknown. Environmental factors, such as smok-ing, diet, and other exposures, do not predispose 
the brain to develop tumors.1 Only a very small pro-
portion of brain tumors are caused by hereditary gene 
defects (Table 1), irradiation, or immune suppression. 
Additional knowledge about the biological characteris-
tics of pediatric brain tumors may provide new informa-
tion about pathogenesis, facilitate diagnosis, contribute 
to better risk-group stratification for therapy, or be used 
to develop new therapeutic targets. To identify these bio-
logical factors, many techniques have been developed 
over the years. In this article, we review newly identi-
fied aberrantly expressed genes and proteins, chromo-
somal changes, DNA copy number abnormalities, and 
other genetic changes that may be important in the 
pathogenesis and biological behavior of two frequent 
pediatric brain tumor subtypes, medulloblastomas and 
ependymomas.
Copyright 2008 by the Society for Neuro-Oncology
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Medulloblastoma
Clinical Aspects
Medulloblastoma is the most common embryonal CNS 
tumor of childhood and is likely composed of biologi-
cally different subsets of tumors arising from stem and/
or progenitor cells of the cerebellum. The World Health 
Organization recognizes at least five different histologi-
cal types of medulloblastoma, and there is increasing 
evidence that prognosis and possibly response to ther-
apy depend on the tumor’s cell of origin and the cellular 
pathways active in tumor development and growth.
Medulloblastomas, which by definition arise in the 
posterior fossa, are conventionally stratified on the basis 
of clinical parameters, such as extent of tumor at the 
time of diagnosis and completeness of surgical resec-
tion, into average-risk and high-risk (poor-prognosis) 
disease.2 For children older than 3 years with nondis-
seminated disease and for partially resected “high-risk” 
disease, standard therapy includes both treatment with 
radiotherapy and adjuvant chemotherapy.3 Five-year 
disease-free survival rates of 80% or more are now being 
reported by multiple groups for patients with average-
risk medulloblastoma, and a major focus of new treat-
ment approaches is the development of innovative ways 
to reduce long-term toxicity of therapy.3 Approaches 
that have been used and are under study include reduc-
tion of the total dose of craniospinal radiation therapy, 
reduction of the volume of local boost radiotherapy, and 
use of less neurotoxic chemotherapeutic agents.3 Even in 
patients with high-risk disease, with current means of 
treatment, 5-year survival rates of 60% or more are now 
being reported.4 Most therapeutic approaches for “high-
risk” patients have continued to use relatively high doses 
of craniospinal radiation therapy and aggressive chemo-
therapeutic approaches.4
The treatment for infants with medulloblastoma 
remains highly problematic. The volumes and doses of 
radiotherapy required for disease control cause signifi-
cant brain injury in patients of all ages and predomi-
nantly manifest as long-term neurocognitive sequelae, 
but they are especially damaging in the very young 
child.5 For this reason, most therapeutic approaches have 
focused on either delaying or eliminating radiotherapy 
by the use of increasingly aggressive chemotherapeutic 
approaches that have incorporated potentially neuro-
toxic drugs, such as methotrexate, or high-dose chemo-
therapy supported by autologous peripheral stem cell 
rescue.6 There is some suggestion that such approaches 
are more effective, but some of these apparent improve-
ments in survival may also be related to separation of 
more aggressive tumors, such as atypical teratoid/rhab-
doid tumors, from the cohort of patients treated or 
the inclusion of lower-risk patients, such as those with 
desmoplastic tumors, in treatment protocols.7 A major 
hope for the future is that the incorporation of biologi-
cal agents targeting specific signaling pathways will not 
Table 1. Hereditary syndromes predisposing to the development of a brain tumor
  CNS Tumor  Involvement in 
Disease Gene (Chromosomal Location) Associated with Disease Sporadic CNS Tumor
Li-Fraumeni syndrome p53 (17p13.1)  Astrocytoma Astrocytoma 
  Medulloblastoma Choroid plexus tumor
Neurofibromatosis type I NF1 (17q11.2) Astrocytoma ?
Neurofibromatosis type II NF2 (22q12.2) Vestibular and spinal schwannoma Meningioma 
  Ependymoma Schwannoma 
  Meningioma
Nevoid basal cell carcinoma  
 syndrome (Gorlin’s syndrome) PTCH (9q22.3) Medulloblastoma Medulloblastoma
Tuberous sclerosis TSC1 (9q34) Subependymal giant-cell tumor ? 
 TSC2 (16p13)  
Turcot’s syndrome A APC (5q21–q22) Medulloblastoma Medulloblastoma
Turcot’s syndrome B MLH1 (3p21.3) Glioblastoma (Astrocytic tumor) 
 MSH2 (2p22–p21) Ependymoma 
 MLH3 (14q24) 
 PMS1 (2q31–q33) 
 PMS2 (7p22) 
Von Hippel Lindau disease VHL (3p25) Hemangioblastoma ?
Cowden disease PTEN (10q22–q23) Astrocytoma Glioblastoma
Melanoma-astrocytoma syndrome CDKN2A (9p21) Astrocytoma Astrocytoma
Rubenstein-Taybi syndrome CBP (16p13.3) Medulloblastoma ? 
  Meningioma 
  Oligodendroglioma 
MEN1 syndrome MEN1 (11q13) Ependymoma Ependymoma 
   Pituitary tumor
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way occur in a substantial number of medulloblastomas 
(Table 2).15,16 Most mutations have been found in the 
b-catenin gene, but mutations in the APC and AXIN2 
genes and deletions of the AXIN1 gene have also been 
described (Table 2). However, deletions of AXIN1 were 
also identified in normal brain tissue, suggesting that at 
least some of the AXIN1 deletions found in medullo-
blastoma represent polymorphisms or PCR artifacts.17 
Another marker associated with activation of the Wnt 
signaling pathway is increased expression of survivin, 
an apoptosis inhibitor (Table 2). Survivin expression 
is related to an unfavorable outcome, independent of 
clinical staging or tumor histology.18,19 SOX gene family 
members can also regulate the Wnt signaling pathway.20 
Interestingly, SOX4 and SOX11 are overexpressed in 
predominantly classic medulloblastoma.21–23
The SHH and Wnt signaling pathways interact with 
each other, but also with other signaling pathways, 
including Notch, ErbB, and insulin-like growth factor 
(IGF) (Fig. 1). For example, cyclin D1, an important 
mediator of the proliferation of cerebellar granule cell 
precursors, is an important downstream target of SHH, 
Wnt, and Notch signaling. Moreover, medulloblastomas 
of PTCH1 1/– mice show increased expression of genes 
involved in activation of both SHH and Wnt signal-
ing.24
Notch Signaling. In the cerebellum, Notch2 is pre-
dominantly expressed in proliferating cerebellar granule 
cell precursors, whereas Notch1 is found in differenti-
ated internal granule layer neurons.25 Notch2 is over-
expressed in a subset of medulloblastomas, whereas 
Notch1 expression is scarce. Activation of the Notch 
signaling pathway results in the transcriptional activa-
tion of helix-loop-helix transcription factors HES1 and 
HES5.26 HES1 expression is associated with decreased 
survival rates of medulloblastoma patients (Table 2). It 
has been recently hypothesized that HES1 forms tran-
scriptional repressor complexes with FOXG1 to nega-
tively regulate the differentiation of neural progenitor 
cells.27 Interestingly, the function of the FOXG1 gene is 
deregulated in most medulloblastomas (Table 2). Treat-
ment of medulloblastoma xenografts with inhibitors of 
the Notch signaling pathway results in decreased prolif-
eration and increased apoptosis.28
ErbB Signaling. ErbB belongs to the receptor 
tyrosine kinase family I, which consists of four receptor 
tyrosine kinases (ErbB1–ErbB4) and a variety of ligands, 
including several neuregulins that are important in reg-
ulating the development of neuronal tissue.29 ErbB4, 
especially the CYT1 isoform, is overexpressed in tumors 
with low Gli1 levels, which suggests that ErbB signal-
ing is regulated by SHH signaling.30 CYT1 is the only 
isoform of ErbB4 that is able to activate antiapoptotic 
phosphatidyl inositol 3-kinase (PI3K)/protein kinase B 
(PKB)/AKT signaling,31 which is important in medullo-
blastoma development. Overexpression of the CYT1 
ErbB4 isoform correlates with the anaplastic medullo-
blastoma subtype and ErbB2 expression levels. Because 
the ErbB2 gene is located on chromosome 17q11.2–q12, 
only make treatment more effective, but also allow a 
reduction in neurotoxic therapy.
Genetic and Biological Aspects
Developmental Signaling Pathways. Several hereditary 
syndromes predispose to the development of a brain 
tumor (Table 1), and the underlying gene defects are 
thought to provide information about the critical genes 
in the pathogenesis of brain tumors. The genes mutated 
in syndromes predisposing to medulloblastoma develop-
ment are frequently involved in cellular signaling path-
ways (Table 2), which are important regulators of brain 
development, such as sonic hedgehog (SHH), Wnt, and 
Notch (Fig. 1).
Sonic Hedgehog Signaling. Gorlin’s syndrome is 
an autosomal dominant disorder that is characterized 
by multiple developmental defects and a predisposi-
tion for basal cell carcinoma, rhabdomyosarcoma, and 
medulloblastoma.8 The tumor suppressor gene Patched 
1 (PTCH1) on chromosome 9q22.3, encoding a trans-
membrane surface receptor for hedgehog proteins, is 
mutated in this syndrome. The hedgehog–Patched sig-
naling pathway controls normal development of the 
external granular layer of the cerebellum.9 SHH, pro-
duced by Purkinje cells, binds to the PTCH1 receptor 
and induces proliferation of cerebellar granule cell pre-
cursors by relieving the inhibition of Smo and induc-
ing activation of the Gli family of transcription factors.9 
Mutations in various components of the SHH pathway, 
such as PTCH1 and Smo, occur in approximately 30% 
of sporadic medulloblastomas, predominantly desmo-
plastic medulloblastomas (Table 2). These tumors show 
up-regulation of important SHH target genes, such as 
Gli1 and BMI1, indicating active SHH signaling. BMI1 
is overexpressed in medulloblastomas, which might 
result in the abnormal regulation of both the Rb and 
p53 pathways.10 The importance of the SHH pathway in 
medulloblastoma is underlined by the observed growth 
inhibition after treatment with inhibitors of the SHH 
pathway.11 Because only a small subset of PTCH1 1/– 
mice develop medulloblastoma, other genetic events are 
thought to influence the susceptibility of developing 
medulloblastoma. For example, concomitant loss of p53 
or Ink4C has been shown to facilitate the development 
of medulloblastoma.12
Wnt Signaling. The Wnt signaling pathway may 
also be involved in regulating the embryonal develop-
ment of the brain. One of the genes involved in this 
pathway, adenomatous polyposis coli (APC), is mutated 
in patients with Turcot’s syndrome, who have a predis-
position to develop colon cancers, glioblastomas, and 
medulloblastomas (Table 2). APC forms a protein com-
plex together with b-catenin, glycogen synthase kinase 
3-b (GSK3-b), and axin.13 Activation of the Wnt path-
way results in decreased b-catenin degradation followed 
by the interaction with TCF/LEF transcription factors 
and activation of Wnt targets, such as c-Myc, cyclin D1, 
and AXIN2.14 Activating mutations in the Wnt path-
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Table 2. Differentially expressed genetic and proteomic markers identified in medulloblastomas and ependymomas
  Percentage of Tumors  
Gene Change Expressing Gene Reference Correlating with
MEDULLOBLASTOMA
SHH signaling    
PTCH1 Mutation 4.8%–13.5% 105–109 Desmoplastic subtype
PTCH2 Overexpression Unknown 16 —
SUFU Mutation 0%–9% 110, 111 Desmoplastic subtype
Smo Mutation 0%–10% 112, 113 Desmoplastic subtype
Gli Overexpression ~30% 16, 24, 28 Desmoplastic subtype
BMI1 Overexpression ~67% 10 —
RENKCTD11 Deletion ~39% 114 —
Wnt signaling    
Axin 1 Mutation 1.2%–5.6% 17, 115, 116 —
 Deletion 12%–41.7% 17, 115 —
Axin 2 Mutation ~3% 117 —
APC Mutation 1.3%–4.3% 118, 119 —
b-catenin Mutation 0.5%–63.8%  15, 116, 118–121 Favorable outcome
Survivin Overexpression 0.5%–50% 18, 19, 122, 123 Unfavorable outcome
SOX4 Overexpression Unknown 21, 22, 124 —
SOX11 Overexpression Unknown 21, 22 —
Cyclin D1 Overexpression Unknown 23, 24 —
Cyclin D2 Overexpression Unknown 24, 124 —
Lef1 Overexpression Unknown 16, 24, 125 —
Notch signaling    
HES1 Overexpression Up to 46% 24, 25, 28 Unfavorable outcome
HES5 Overexpression Up to 71% 24, 28 —
JAG1 Overexpression Unknown 24 —
Notch1 Overexpression ~75% 27 —
Notch2 Overexpression 12.5%–15% 24, 25, 28 —
Notch3 Overexpression Unknown 24 —
FOXG1 Overexpression .90% 126 —
Mushashi Overexpression Unknown 124 —
ErbB signaling    
ErbB4 Overexpression ~66% 29, 31, 32, 126 Unfavorable outcome
ErbB2 Overexpression 70%–86% 126, 127 Unfavorable outcome
CIC Overexpression Unknown 128 —
NRG-1b	 Overexpression ~87% 29 —
c-myc Amplification 5%–10% 40, 129–133 Anaplasia and 
 Overexpression ~42%  unfavorable outcome
MnT Underexpression ~43% 134, 135 —
n-myc Amplification ~5% 24, 39, 40, 130, 136  Unfavorable outcome 
   137, 138
JPO2 Overexpression Unknown 139 Metastases
BCAT1 Overexpression Unknown 22 Metastases
IGF signaling    
IGF-1R Expression/phosphorylation ~80% 140 —
IRS-1 Overexpression Unknown 140 —
IGF-2 Overexpression Unknown 38, 45 Desmoplastic subtype
AKT/PKB Phosphorylation Unknown 140 —
Erk-1 Phosphorylation Unknown 140 —
Erk-2 Phosphorylation Unknown 140 —
IGFBP-2 Overexpression Unknown 48 —
IGFBP-3 Overexpression Unknown 48 —
(continued)
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Table 2. Differentially expressed genetic and proteomic markers identified in medulloblastomas and ependymomas (continued)
  Percentage of Tumors  
Gene Change Expressing Gene Reference Correlating with
Other    
CXCR4 Overexpression ~51% 16, 141  Desmoplastic and extensive  
nodularity subtype
PDGFRB Overexpression Unknown 142 Metastatic medulloblastoma
OTX2 Overexpression .70% 53, 54, 124, 143, 144 Classic subtype and 
 Amplification ~33%  anaplastic features  
    —
ATOH1 Expression Unknown 16 Desmoplastic subtype
p75NTR Expression Unknown 49, 145  Desmoplastic subtype and 
unfavorable outcome?
TrkA Overexpression ~67% 146 Apoptotic index
TrkC Overexpression 29%–73% 40, 146–150 Favorable outcome
Heparanase Expression 62%–88% 150, 151 —
NEUROG1 Expression ~55% 152, 153  Nondesmoplastic metastatic 
medulloblastoma and unfa-
vorable outcome
Calbindin Expression ~41% 154  Nondesmoplastic medulloblas-
toma and tumor recurrence
p53 Mutation 0%–11% 155–157 Unfavorable outcome
PAX5 Overexpression ~70% 159 —
MDM2 Overexpression 0%–20% 155, 160  Unfavorable outcome in 
adults
CDK6 Overexpression ~30% 63 Unfavorable outcome
HIC1 Hypermethylation ~70% 161, 162 Unfavorable outcome
EEF1D Overexpression Unknown 163 Unfavorable outcome
RPL30 Overexpression Unknown 163 Unfavorable outcome
RPS20 Overexpression Unknown 163 Unfavorable outcome
STMN1 Overexpression Unknown 23, 164 Unfavorable outcome
hTERT Overexpression ~42% 165, 166 Tumor progression
SGNE1/7B2 Hypermethylation ~70% 38, 167 Classic medulloblastoma
RASSF1A Hypermethylation 80%–90% 72, 161 —
CASP8 Hypermethylation ~90% 74, 161, 168–171  Classic and anaplastic subtype 
and unfavorable outcome
ZIC2 Hypermethylation Unknown 75 —
p14ARF Hypermethylation 4%–50% 161 —
p16INK4A Hypermethylation 2%–14% 161, 168, 172, 173 —
TIMP3 Hypermethylation 0%–11% 161, 168, 172 —
CDH1 Hypermethylation ~8% 168 —
p18INK4C Hypermethylation ~20% 174 —
S100A6 Hypermethylation ~12% 175 Large-cell anaplastic subtype
S100A10 Hypermethylation ~12% 175 —
S100A4 Hypomethylation ~17% 175 Metastatic medulloblastoma
MCJ Hypermethylation ~33% 176 
RB1 Hypermethylation ~18% 177 
DKK1 Histone acetylation Unknown 178 
EPENDyMOMA
SHH signaling    
Gli1 Overexpression Unknown 88 —
Gli2 Overexpression Unknown 88 —
Cyclin D1 Overexpression Unknown 83, 88 Supratentorial ependymoma
Wnt signaling    
EB1 Underexpression Unknown 87 —
Notch signaling    
HES1 Overexpression Unknown 88 —
JAG1 Overexpression Unknown 83 Supratentorial ependymoma
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Table 2. Differentially expressed genetic and proteomic markers identified in medulloblastomas and ependymomas (continued)
  Percentage of Tumors  
Gene Change Expressing Gene Reference Correlating with
JAG2 Overexpression Unknown 83 Supratentorial ependymoma
Notch1 Overexpression Unknown 88 —
Notch2 Overexpression Unknown 88 —
FZD1 Overexpression Unknown 88 —
HEY2 Overexpression Unknown 88 —
EPHB-EPHRIN signaling    
EPHRIN A3 Overexpression Unknown 83 Supratentorial ependymoma
EPHB3 Overexpression Unknown 83 Supratentorial ependymoma
EPHB2 Overexpression Unknown 83 Supratentorial ependymoma
ErbB signaling    
ErbB4 Overexpression .75% 179  Proliferation activity and 
unfavorable outcome
ErbB2 Overexpression .75% 179  Proliferation activity and 
unfavorable outcome
IGF signaling    
IGF-1R Expression  29%–80% 180 Anaplastic ependymoma?
IGF-2 Overexpression Unknown 48, 181 —
IGFBP-2 Overexpression Unknown 48 —
IGFBP-3 Overexpression Unknown 48 —
IGFBP-5 Overexpression Unknown 48 —
Other    
NF2 Mutation 10%–71% 182–184 Spinal ependymoma 
 Hypermethylation 0%–7% 185, 186 —
SCHIP1 Underexpression Unknown 87 —
MEN1 Mutation ~2% 82, 187 Recurrent ependymoma
SULT4A1 Underexpression Unknown 88 —
SOX9 Overexpression Unknown 164 Favorable outcome
Calcyphosine Expression ~59% 164 Epithelial differentiation
hTERT Amplification ~24% 98, 188  Proliferation activity and 
unfavorable outcome
CBX7 Underexpression ~55% 87 —
p53 Mutation 0%–6% 185, 189–192 —
MDM2 Amplification 4%–35% 189, 193 —
p73 Overexpression Unknown 194, 195 Grade II ependymoma 
 Hypermethylation 5%–33% 186, 196, 197 —
p14ARF Deletion 1%–7% 83, 98 Supratentorial ependymoma 
 Hypermethylation 0%–28% 196–198 Adults
p15INK4B Hypermethylation 0%–21% 196, 198 Adults
p16INK4A Deletion 1%–7% 83, 98 Supratentorial ependymoma 
 Hypermethylation 0%–32% 88, 186, 196, 197 Adults
RASSF1A Hypermethylation 56%–86% 185, 198 —
CASP8 Hypermethylation 4%–50% 185, 186, 196 Myxopapillary ependymoma
DAPK Hypermethylation 0%–57% 88, 185, 186, 197 —
MGMT Hypermethylation 0%–20% 88, 185, 186, 196, 198 —
FHIT Hypermethylation 22% 185 —
TFRSF10C Hypermethylation 9%–50% 185 —
TFRSF10D Hypermethylation 36% 185 —
BLU Hypermethylation 14% 185 —
RARB Hypermethylation 0%–15% 88, 185 —
THBS1 Hypermethylation 0%–30% 186, 196 —
TIMP3 Hypermethylation 0%–40% 186, 196, 197 —
RB1 Hypermethylation 0%–14% 177, 185, 197 —
MCJ Hypermethylation 10% 175 —
GSTP1 Hypermethylation 28% 197 —
HIC1 Hypermethylation 83% 88, 199 —
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a region that is frequently gained in medulloblastomas, 
ErbB2 is regarded as a potential medulloblastoma onco-
gene. ErbB2 expression, especially in combination with 
high ErbB4 expression, has poor prognostic impact in 
medulloblastoma and is associated with the presence of 
metastases and a high mitotic index.29,32 Overexpression 
of ErbB2 increases the migration of medulloblastoma 
cells in vitro, and prometastatic genes involved in, for 
example, cell adhesion and invasion are up-regulated 
by ErbB2.33 Approximately one-third of the medullo-
blastomas coexpressing ErbB2 and ErbB4 also express 
the ErbB ligand NRG1-b, suggesting an autocrine loop 
resulting in disease progression. Interestingly, one of the 
targets of NRG1-b is c-myc.34 
c-myc Signaling. c-Myc belongs to the myc tran-
scription factor family, which is important in cell cycle 
regulation, proliferation, and differentiation and is 
involved in many human malignancies.35 c-Myc over-
expression in medulloblastoma is associated with the 
large-cell/anaplastic subtype and poor survival (Table 
2). c-myc activation can be caused by activation of the 
SHH and Wnt pathways,36 translocations, activating 
mutations, viral insertion, and genomic amplification. 
In mouse models, c-Myc alone is not sufficient to induce 
medulloblastomas, but it is suggested that c-Myc cooper-
ates with SHH in the pathogenesis of medulloblastoma.37 
The c-Myc binding protein JPO2 can potentiate c-Myc 
transforming activity and is associated with metastatic 
medulloblastoma (Table 2). We observed up-regulation 
of mRNA levels of BCAT1, a myc target, in metastatic 
medulloblastoma and also detected the BCAT1 protein 
in the cerebrospinal fluid of medulloblastoma patients.22 
Another member of the myc family, n-myc, is amplified in 
approximately 5% of medulloblastomas and is an impor-
tant and direct target of the SHH signaling pathway 
promoting cell cycle progression in the developing cer-
ebellum (Table 2). In concordance, n-myc up-regulation 
is observed in medulloblastoma associated with acti-
vated SHH signaling.38,39 n-myc amplification correlates 
with unfavorable survival, but this correlation is less 
clear than for c-myc.40 Prevention of n-Myc degradation 
by PI3K41 may provide an explanation for the enhanc-
ing effect of IGF/PI3K signaling pathway on the SHH-
related development of medulloblastoma.39
IGF/PI3K Signaling. The IGF system also plays an 
important role in neuronal development and is involved 
in the development of brain tumors.42 Most medullo-
blastomas overexpress the IGF-1 receptor (IGF-1R) pro-
tein, and more than half of medulloblastomas express 
the activated phosphorylated form of IGF-1R (Table 
2). Moreover, activated forms of downstream signal-
ing molecules of IGF-1R, such as insulin receptor sub-
strate-1 (IRS-1), PI3K, AKT/PKB, Erk-1, and Erk-2, are 
detected in most medulloblastomas. Inhibition of IGF-
1R signaling reduces medulloblastoma tumor growth.43 
This inhibition is augmented by constitutive GSK3-b 
phosphorylation,44 suggesting that the combined inhibi-
tion of the IGF-1R and dephosphorylation of GSK3-b 
might be an effective treatment for medulloblastoma. 
The IGF-1R ligands IGF-1 and IGF-2 are important 
Fig. 1. Signaling pathways involved in the development of the brain and pathogenesis of medulloblastoma and ependymoma. Deregula-
tion of these pathways is important in the pathogenesis of medulloblastoma and ependymoma. Interactions among these pathways are 
multiple and complex.
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mitogens in cerebellar granule precursors and medullo-
blastoma.45,46 Patti et al.46 showed the presence of an 
autocrine loop causing IGF-1R activation and leading to 
proliferation in a medulloblastoma cell line. IGF-2 is a 
downstream target of SHH signaling,47 and in concor-
dance, IGF-2 overexpression is predominantly observed 
in desmoplastic medulloblastomas. The IGF-binding 
proteins (IGFBPs) modulate IGF action and are differ-
entially expressed in brain tumors. We have observed 
increased IGFBP-2 and IGFBP-3 mRNA expression 
levels in medulloblastoma, which is accompanied by 
increased IGFBP-3 levels and IGFBP-3 proteolysis 
in the cerebrospinal fluid of brain tumor patients.48 The 
IGF-1R signaling pathway may result in activation of 
AKT and PI3K, and also ras/MAPK (mitogen-activated 
protein kinase) signaling. Downstream targets of the 
ras/MAPK pathway and platelet-derived growth factor 
receptor B (PDGFRB) are up-regulated in metastatic 
medulloblastoma (Table 2).
Cells of Origin
Lateral Cerebellar Hemispheres. Activation of differ-
ent signaling pathways in different medulloblastoma 
subtypes suggests that medulloblastomas have different 
origins. Potential cells of origin are the stem and/or pro-
genitor cells in the external granular layer that have per-
sisted after the first years of life and the pluripotent stem 
cells of the ventricular subependymal matrix, which are 
capable of differentiating into neuronal or glial cells. 
Several findings support this hypothesis of double origin. 
Desmoplastic medulloblastomas are usually found in the 
cerebellar hemispheres and are thought to arise from 
neural precursor cells in the external granule layer.49 In 
concordance, they are characterized by activated SHH 
signaling and IGF-2 overexpression, which affects the 
proliferation of cerebellar granule precursors. CXCR4, 
ATOH1, and the p75 neurotrophin receptor (p75NTR) 
are markers of the stem and/or progenitor cells in the 
external granular layer and are predominantly found 
in desmoplastic medulloblastomas (Table 2). CXCR4 is 
important for migration and cell cycle control of granu-
lar precursors and is a target of SHH. Aberrant acti-
vation of the CXCR4 receptor might contribute to an 
increased malignant potential, but mutations in CXCR4 
are only rarely observed in medulloblastoma. ATOH1 is 
a basic helix-loop-helix transcription factor that influ-
ences the development of granular cerebellar precursors 
via the Notch pathway.50 p75NTR belongs to the family 
of neurotrophins and neurotrophin receptors, which are 
important in the normal development of the cerebel-
lum.51 Expression of p75NTR is suggested to be a marker 
of tumor progression (Table 2). Another neurotrophin 
receptor, TrkC, is one of the first biological markers in 
medulloblastoma and is a strong predictor of favorable 
outcome (Table 2), probably because binding of the TrkC 
ligand to the receptor induces apoptosis.51
Cerebellar Vermis. In contrast to desmoplastic 
medulloblastomas arising in the lateral cerebellar hemi-
spheres, medulloblastoma subtypes arising in the cere-
bellar vermis are suggested to originate from cells in the 
ventricular matrix and Purkinje neurons. Calbindin and 
NeuroG1 expression are specific for stem and/or pro-
genitor cells in the cerebellar ventricular zone. Calbindin 
is expressed in most classic medulloblastomas, and its 
expression may be a marker for recurrence in medullo-
blastoma (Table 2). NeuroG1 (NeuroD3) belongs to the 
NeuroD family of basic helix-loop-helix transcription 
factors, regulating the transcription of genes involved in 
neuronal differentiation.52 NeuroG1 expression is cor-
related with the overexpression of myc and is indicative 
of a poor prognosis in medulloblastoma (Table 2).
OTX2 (head development gene) overexpression, 
observed in more than two-thirds of medulloblastomas, 
is also characteristic for the classic medulloblastomas 
arising in the cerebellar vermis (Table 2). However, 
because cells of the fetal external granular cerebellar 
layer are also shown to express OTX2, a subset of clas-
sic medulloblastomas negative for calbindin may also 
arise from the external granular layer.53 OTX2 expres-
sion is correlated to the presence of proliferating, poorly 
differentiated cells with anaplastic features, but no cor-
relation with outcome has been observed. Amplification 
of OTX2 occurs in up to one-third of primary medullo-
blastomas, but mutations have not been identified. 
OTX2 knockdown, either by small interfering RNAs or 
by treatment with all-trans-retinoic acid, induced apop-
tosis in vitro, which suggests that OTX2 might be an 
interesting therapeutic target.54
Cytogenetics. Much knowledge about cytogenetic 
abnormalities of brain tumors has been obtained by 
conventional cytogenetic, loss of heterozygosity (LOH), 
and molecular genetic analyses, for example, compara-
tive genomic hybridization (CGH). Karyotyping reveals 
that balanced translocations are relatively infrequent 
in medulloblastomas (Table 3) compared with chromo-
somal gains and losses. No recurrent translocations have 
thus far been identified in medulloblastoma. Fig. 2 sum-
marizes the chromosomal gains and losses in medullo-
blastomas identified by CGH. Conventional CGH can 
detect regions of copy number change, and the recent 
development of array-based CGH has resulted in higher-
resolution analyses allowing more precise definition of 
which regions are involved. In addition, correlation of 
these data with gene expression levels may identify genes 
that are potentially important driver genes in these copy 
abnormalities.
Chromosome 17. The most commonly reported 
cytogenetic change in medulloblastoma is loss of 17p in 
up to approximately 50% of medulloblastomas, often 
associated with a gain of 17q leading to the formation 
of an isochromosome 17q [i(17q)].55 Because i(17q) can 
be found as a single structural abnormality, it may be 
a primary event in medulloblastoma development. In 
some studies, loss of 17p was associated with a poor 
prognosis, while others failed to find this associa-
tion.56,57 The incidence of i(17q) is low in desmoplastic 
medulloblastoma compared with classic and large-cell 
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anaplastic medulloblastoma. Despite the identification 
of several common chromosomal breakpoint regions at 
17p11.2, 17p11.2–17q11.2, and 17q21.31 and various 
commonly deleted regions on 17p, for example, 17p13.1 
and 17p13.3,58,59 the affected tumor suppressor gene 
involved in the pathogenesis of medulloblastoma has not 
been identified thus far.
p53, one of the most important tumor suppressor 
genes, was initially suggested to be of importance in 
Table 3. Balanced chromosomal translocations identified in medulloblastomas and ependymomas.
Medulloblastoma Reference Ependymoma Reference
t(1;3)(p13;p13) 200 t(1;2)(p33;q21) 201
t(1;3)(q32;q27) 202 t(1;2)(q21;q35) 203
t(1;4)(q31;q35) 204 t(1;3)(p34;q21) 203
t(1;6)(p21;q11–13) 205 t(1;7)(q25;q35) 206
t(1;8)(q1?;q2?) 207 t(1;8) 201
t(1;8)(q25;q22) 208 t(1;9)(p36;q13) 209
t(1;11)(q32;p15) 210 t(1;14)(q?;p?) 210
t(1;14)(p22;q31) 211 t(1;20)(q21;q13) 201
t(1;15)(p36;q11) 210 t(1;22)(q11;q13) 212
t(2;12)(q21;q23) 210 t(2;4)(q34;q35) 213
t(2;15)(q37;q15) 214 t(2;10)(p25;q12) 213
t(3;6)(p21;q12) 214 t(2;17)(p11;p11) 201
t(3;9)(q27;q22) 210 t(2;22)(p12;q13) 211
t(3;12)(p21;q13) 210 t(2;22)(p13;q13) 215
t(3;17)(p13;p13) 210 ?t(3;3)(q29;q25) 216
t(5;6)(q13;q21) 214 t(3;4)(q?;q?) 210
t(5;8;10)(q34;q24;q24) 210 t(3;6)(q11;q11) 215
t(6;13)(q25;q14) 202 t(3;11)(q29;q25) 217
t(6;14)(q27;q11) 202 t(3;15)(q?;q?) 210
t(6;19)(q21;q13) 204 t(4;22)(p16;p13) 217
t(7;13)(q11;q34) 208 t(6;11)(p?;q?) 210
t(7;19)(p11;p11) 210 t(6;11)(q27;q25) 217
t(9;11)(q34;q13) 200 t(6;16) 219
t(9;19)(q22;q13) 201 t(9;11)(q34;q25) 217
t(10;16) 207 t(9;16)(q?;q?? 210
t(11;13)(p13;q14) 202 t(9;17)(q34;q25) 217
t(11;13)(q15;q11) 204 t(10;11;15)(p12;q13;p12) 220
t(12;13)(p13;p11) 201 t(11;12)(q13;q24) 187
t(12;21) 218 t(11;17)(q13;q21) 218
t(13;14)(q11;p11) 201 t(11;17)(q25;q25) 217
t(13;15)(q32;q22) 210 t(11;18)(q13;q21) 201
t(?15;16)(q13;p13) 138 t(11;19)(q25;q13) 217
t(16;17)(q?;q?) 221 t(12;18)(p11;q11) 201
t(16;20)(q13–22;q13)  55  
t(17;17)(p?;p?) 218  
t(17;18)(p11;q11) 202  
t(18;22)(q23;q11) 202  
t(18;20)(q23;p13) 222  
t(X;15)(p22;q25) 210  
t(X;18)(p11;q11) 201  
t(X;22)(p22;q11) 223  
Source: Mitelman Database of Chromosome Aberrations in Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman).
Fig. 2. Copy number aberrations and amplifications in medulloblasto-
mas (n 5 455)56,65,67,68,70,136,163,165,202,224-236 and ependymomas (n 5 
354)97,99,100,113,237–245 by CGH. Some studies provided only a sum-
mary of data62–64,88,98 or did not distinguish between medulloblas-
tomas and primitive neuroectodermal tumors,246 and we excluded 
those results here. The numbers at the tops of the graphs indicated 
chromosome number.
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medulloblastoma, because it is localized on chromosome 
17p13. However, despite the facts that (1) patients with 
germline p53 mutations have a predisposition to develop 
medulloblastomas (Table 1), (2) loss of p53 facilitates 
medulloblastoma development in mouse models,12 and 
(3) up to 40% of medulloblastomas show p53 protein 
expression indicating a dysfunctional p53 protein, we 
and others have shown that the incidence of p53 muta-
tions in sporadic medulloblastoma is low (Table 2). 
Overexpression of the p53 binding protein MDM2, 
known to cause inactivation of p53, is also very rare in 
medulloblastomas (Table 2). p53 inhibition by PAX5 
(early development gene) is suggested to play a role in 
medulloblastomas as the expression of PAX5 is deregu-
lated in approximately 70% of cases (Table 2).
Besides p53, several other candidate tumor suppres-
sor genes on 17p have been suggested. Interestingly, 
17p carries several genes suggested to be involved in the 
regulation of SHH signaling. HIC1, located on 17p13.3, 
is aberrantly methylated in medulloblastoma, and the 
subsequent transcriptional silencing is associated with 
poor outcome (Table 2). Recently, loss of HIC1 together 
with loss of PTCH1 was found to result in a higher inci-
dence of medulloblastomas.60 This is probably related to 
the cooperation of HIC1 and PTCH1 in the silencing of 
ATOH1 expression, which is required for medulloblas-
toma growth. RENKCTD11, a putative tumor suppres-
sor gene located on chromosome 17p13.2, is deleted in 
39% of medulloblastomas (Table 2). RENKCTD11 inhib-
its medulloblastoma cell proliferation by antagonizing 
the activation of SHH target genes. Deletion of this 
gene might thus result in enhanced SHH signaling and 
increased proliferation of granule cell precursors. The 
myc inhibitor MnT, mapped to 17p13.3, is also deleted 
or underexpressed in medulloblastoma. Because c-myc 
and n-myc are both targets of SHH signaling, loss of 
the Mnt gene on 17p might again link this chromosomal 
abnormality to SHH signaling.
Gain of 17q can also occur in the absence of a 17p 
deletion, suggesting that duplication of genes on 17q 
influence medulloblastoma development. An amplicon 
on 17q23.2 contains the APPBP2 and PPM1D genes.59 
PPM1D overexpression can, for example, inhibit p53 
tumor suppressor activity.61 Because the regions of loss 
of 17p and gain of 17q are large, the gene dosage effect 
of genes on 17p and 17q, rather than one tumor suppres-
sor gene, may be tumorigenic in medulloblastoma.59
Chromosome 7. A cytogenetic abnormality that is 
often seen in combination with a gain of 17q is gain of 
chromosome 7. As for chromosome 17, the gene of inter-
est is not yet identified. Hui et al.62 found an amplifi-
cation core at 7q34–q35 containing several oncogenes. 
A novel amplicon at 7q21.2 contained only the CDK6 
gene. Cyclin-dependent kinase 6 (CDK6) can phospho-
rylate retinoblastoma 1 (RB1), which is an important 
regulator of proliferation and differentiation. CDK6 is 
overexpressed and indicates poor prognosis in medullo-
blastomas (Table 2).
Other Copy Number Abnormalities. Other recurrent 
abnormalities in medulloblastomas are losses on 6q, 8p, 
9q, 10q, 11, 16q, 20, X, and Y and gains on 1q, 2p, 4q, 
6q, 9p, 13q, 14q, and 18 (Fig. 2). Several regions with 
consistent copy number gain have been identified on 1q, 
for example, 1q21.3–23.1,62 1q32.1,62,63 and 1q32.3–
qter.63,64 HLX1 is suggested to be involved in the gain 
on 1q, because its expression was markedly increased in 
medulloblastomas.65 Concerning losses on 6q, a small 
region of deletion is identified at 6q23.1.62 The com-
monly deleted region on 8p is localized between 8p21.3 
and 8p23.2, adjacent to the tumor suppressor gene 
DLC1.64,66 The minimal region of overlap of losses on 
chromosome 16q is at the distal end of 16q, at 16q22.2–
qter.67 Regarding losses of chromosome 10, several 
minimal regions of overlap are observed, one involving 
the 10q23 region containing the PTEN gene, another 
involving a hemizygous deletion in 10q25.1, and a third 
involving the 10q26.3 region.67–69 The SUFU gene, 
described as being mutated in a small subset of medullo-
blastomas, maps to 10q24.3 and is therefore suggested 
to have a role as tumor suppressor gene (Table 2). Loss 
of 11p is identified in 10%–20% of medulloblastomas 
(Fig. 2). However, LOH analyses show allelic loss of 
11p in .50% of tumors.69 Minimal overlapping regions 
of loss on chromosome 11 are 11pter–11p11.2 and 
11q13.2–11qter. The region of gain on 14q is mapped 
to 14q12 and contains the FOXG1 gene, which is aber-
rantly expressed in most medulloblastomas (described 
above; see “Notch Signaling”). Loss of chromosome 20 
frequently involves the whole chromosome. However, 
recently the commonly deleted region on chromosome 
20 is identified at 20q13.2–q13.3,62,64 but no target 
genes have been identified yet.
Amplifications. Gene amplifications are relatively rare 
in medulloblastomas. The identified amplification sites 
are displayed in Fig. 2. Several potential oncogenes are 
involved in these amplifications. MYCL1 is an important 
candidate gene in the amplification region on chromo-
some 1p34.64 The c-myc and n-myc genes on chromo-
somes 8q24 and 2p24, respectively, are amplified in a 
small proportion of tumors, mainly large-cell anaplastic 
medulloblastoma (Table 2). However, gain of 8q, includ-
ing the three ribosomal genes EEF1D, RPL30, and 
RPS20, is also predictive of poor outcome independent 
of myc (Table 2). The amplicon on 5p15 involves the 
hTERT gene, known to be amplified and overexpressed 
in medulloblastoma (Table 2). hTERT is able to com-
pensate for progressive telomere shortening, leading to 
immortalization. Amplification of hTERT is associated 
with tumor progression in medulloblastoma. Further 
analysis of the 9p amplification suggested the importance 
of the 9p23–p24 region, including the JMJD2C gene. The 
11q22.3 region maps the cyclin D1 locus, which is ampli-
fied in a variety of tumors. A possible candidate gene for 
the 13q34 amplification is IRS-2,70 which is amplified 
and overexpressed in a small subset of glioblastomas.
Epigenetics. Recently, epigenetic changes have also been 
shown to be important in tumorigenesis. Both histone 
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modifications (acetylation, methylation, and phospho-
rylation) and hypermethylation of CpG motifs in pro-
moter regions may induce transcriptional silencing of 
tumor suppressor genes.71 Several putative tumor sup-
pressor genes are aberrantly methylated in subgroups of 
medulloblastoma (Table 2). RASSF1A (RAS association 
domain gene) regulates cyclin D1 expression, which is 
important in controlling the cell cycle. In contrast to 
other malignancies, hypermethylation of RASSF1A in 
medulloblastoma is not accompanied by allelic loss of 
3p21.3 or mutation, indicating that biallelic loss is the 
primary mechanism of inactivation of RASSF1A.72 
CASP8 is a cysteine protease involved in death-receptor- 
mediated apoptosis.73 We and others have shown that 
promoter hypermethylation of CASP8 leading to loss of 
CASP8 mRNA expression induces resistance to apopto-
sis induced by tumor necrosis factor–related apoptosis-
inducing ligand (TRAIL) in embryonal tumors of child-
hood, such as medulloblastoma and neuroblastoma.74 
In primary tumors, aberrant promoter methylation of 
CASP8 was seen most frequently in classic and anaplastic 
medulloblastoma and is an independent unfavorable prog-
nostic factor. Transcriptional silencing of SGNE1/7B2, 
a gene located on 15q11–15, occurs predominantly in 
classic medulloblastoma. SGNE1 is a calcium-dependent 
serine protease that inhibits tumor cell proliferation. 
ZIC2 is a zinc-finger transcription factor essential for the 
developing CNS, and its expression is down-regulated in 
medulloblastomas.75 p18INK4C is a CDK inhibitor, and loss 
of expression of this gene can induce medulloblastoma in 
mouse models in collaboration with loss of PTCH1 or 
p53.76 Three members of the S100 gene family are found 
to be aberrantly methylated in 10%–20% of medullo-
blastomas (Table 2). Hyper methylation and silencing of 
S100A6 is associated with the large-cell anaplastic sub-
type of medulloblastoma. In contrast, S100A4 is hypom-
ethylated, which results in increased expression. The 
prometastatic gene S100A4 is a direct target of ErbB2 sig-
naling, associated with a poor prognosis in medulloblas-
toma. MCJ, a member of the DNAJ protein family that 
influences chemotherapy resistance, can be inactivated by 
biallelic hypermethylation, but hypermethylation of one 
allele also occurs in combination with genetic loss of the 
second allele (Table 2). Dickkopf-1 (DKK1) is epigeneti-
cally silenced in medulloblastoma by histone acetylation 
in the promoter region (Table 2). DKK1, a Wnt signaling 
antagonist, is an important suppressor of cell growth and 
inducer of apoptosis.
Proteomics. Despite enormous progress in applications 
and sensitivity, proteomic techniques are not frequently 
used to screen for aberrantly expressed proteins in brain 
tumors. The proteome of two representative medullo-
blastoma cell lines, DAOY and D283MED, has been 
studied by two-dimensional gel electrophoresis with sub-
sequent matrix-assisted laser desorption/ionization iden-
tification.77 Several proteins described previously in other 
malignancies, such as SIP or HSP27 and other new candi-
date tumor-related proteins, were identified. We studied 
protein expression profiles of primary medulloblastomas 
using two-dimensional difference gel electrophoresis fol-
lowed by mass spectrometry and found STMN1 to be 
overexpressed in medulloblastoma (Table 2).
Ependymoma
Clinical Aspects
Ependymomas, predominantly occurring in the poste-
rior fossa in childhood, may also arise supratentorially 
and account for approximately 10% of all intracranial 
tumors in childhood and a higher proportion, up to 
30% in some series, in children younger than 3 years.78 
A variety of different subtypes of ependymomas have 
been identified, and the anaplastic variant seems to carry 
a worse prognosis.78,79 Surgery remains a major compo-
nent of the management of ependymomas, and patients 
with posterior fossa ependymomas who have tumors 
amenable to gross total resections and are subsequently 
treated with radiotherapy have a 70% or greater likeli-
hood of long-term disease control and possible cure.
Recent studies have focused on the utility of chemo-
therapy followed by second-look surgery prior to radio-
therapy in those patients whose tumors are not totally, 
or near-totally, resected.80 Increasing evidence suggests 
that ependymomas are chemosensitive, but in older chil-
dren chemotherapy has been primarily reserved for those 
patients with subtotally resected tumors or with ana-
plastic lesions. Conformal radiation therapy techniques 
are primarily used in children with ependymomas, and 
radiotherapy has now been used in cooperative group 
studies in children as young as 1 year. In very young 
children, especially those younger than 1 year, treatment 
with chemotherapy is often used in attempts to delay 
and, in select cases, obviate the need for radiotherapy, 
but high-dose chemotherapeutic regimens supported 
by autologous peripheral stem cell rescue have not been 
effective.80 The incidence of leptomeningeal dissemi-
nation at the time of diagnosis has varied significantly 
among series, but in general, less than 10% of children 
will have disseminated disease at the time of diagnosis, 
and craniospinal radiotherapy is reserved for those with 
documented disseminated disease. Increasing evidence 
suggests that supratentorial ependymomas differ biolog-
ically from those arising in the posterior fossa. Although 
standard treatment of partially resected supratentorial 
ependymomas is the same as for partially resected pos-
terior fossa tumors, studies are evaluating the efficacy 
of surgery alone for totally resected supratentorial 
tumors.
Genetic and Biological Aspects
Developmental Signaling Pathways. Unfortunately, 
biological characteristics of ependymomas are largely 
unknown. This is mainly because ependymoma is a het-
erogeneous disease and can be subdivided into a wide 
range of subgroups based on histology and localization, 
which results in relatively small series of patients.
NF2. As in medulloblastomas, genetic syndromes 
associated with a predisposition to develop ependymo-
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mas, such as neurofibromatosis type 2 (NF2) (Table 1), 
were initially thought to provide clues about the genetic 
abnormalities involved in the pathogenesis of ependymo-
mas. The NF2 gene is located on 22q12, and because 
allelic loss of chromosome 22 is frequently observed in 
ependymomas, NF2 was suggested to be a tumor sup-
pressor gene involved in the development of ependymo-
mas. However, mutations of the NF2 gene are rarely 
observed in sporadic ependymomas, except for the spinal 
ependymomas (Table 2). Inactivation of NF2 by hyper-
methylation is also rare (Table 2). Interestingly, although 
NF2 does not play an important role in sporadic non-
spinal ependymomas, the expression of SCHIP-1, an 
NF2-interacting gene, is significantly down-regulated in 
pediatric ependymomas (Table 2).
MEN1. Other hereditary forms of ependymoma 
are uncommon. Ependymomas have been described in 
patients with MEN1 syndrome, which is characterized 
by the development of multiple endocrine tumors.81 The 
MEN1 gene is located on chromosome 11q13, a region 
that is involved in allelic losses and rearrangements in 
ependymomas.82 However, mutations in the MEN1 
gene are described in only a small number of recurrent 
ependymomas (Table 2).
An important recent finding is that gene expression sig-
natures of ependymomas from different locations of the 
CNS correlate with those of the corresponding region 
of the normal developing CNS.83 The differentially 
expressed genes are predominantly involved in the regu-
lation of neural precursor cell proliferation and differen-
tiation. In addition, ependymomas contain rare popula-
tions of cancer stem cells resembling radial glial cells, 
which are sufficient to give rise to tumor development 
in mice.83 Therefore, these radial glial cells in different 
parts of the CNS may be predisposed to acquire distinct 
genetic abnormalities that transform them into cancer 
stem cells of supratentorial, infratentorial, and spinal 
ependymomas. These data imply that signaling pathways 
involved in the development of the brain and neural stem 
cells, such as Notch, Wnt, SHH, and p53, are important 
in the pathogenesis of ependymomas (Fig. 1).
EPHB-EPHRIN and Notch Signaling. Active 
EPHB-EPHRIN (intercellular tyrosine kinase signalling) 
and Notch signaling is indeed observed in ependymo-
mas, especially in those located in the supratentorial 
region (Table 2). Both signaling pathways are important 
for the maintenance of neural stem cells in the cere-
bral subventricular zone.84,85 The overexpression of the 
Notch target ErbB2 in most ependymomas and its cor-
relation with proliferation and poor outcome also point 
to the importance of Notch signaling in ependymomas.
Wnt Signaling. Ependymomas have been described 
in patients with APC mutations associated with Tur-
cot’s syndrome.86 However, in contrast to medulloblas-
tomas, mutations in APC and b-catenin are not found 
in sporadic ependymomas (Table 2). Despite the absence 
of these mutations, gene expression profiling identifies 
aberrantly expressed genes involved in the Wnt signaling 
pathway, suggesting alternative mechanisms for disrup-
tion of this pathway.87
SHH Signaling. Involvement of SHH signaling in 
ependymomas is suggested by the overexpression GLI2, 
GLI-Kruppel family member (Gli), and serine threonine 
kinase 36 (STK36) and underexpression of PRKAR1B.88 
In addition, overexpression of the SHH target IGF-2 is 
frequently observed in these tumors (Table 2). Besides 
the overexpression of IGF-2, we have found overexpres-
sion of IGFBP-2, -3, and -5 in ependymomas, also sug-
gesting the involvement of the IGF system in the patho-
genesis of ependymomas.48
p53 Signaling. Only one patient with a germline 
p53 mutation has been reported with an ependymoma.89 
Despite the fact that p53 immunostaining is suggested 
to be associated with an unfavorable prognosis,90 p53 
mutations are extremely rare in sporadic ependymomas 
(Table 2). Other methods of p53 inactivation have been 
observed in subgroups of ependymomas but are also 
relatively uncommon. Some report a high incidence of 
mdm2 expression and amplification in ependymomas, 
whereas others conclude that mdm2 plays a role in only a 
very small number of patients (Table 2). p73, a gene that 
shares structural and functional homologies with p53 
and is able to induce mdm2, is overexpressed in grade II 
ependymoma (Table 2). Inhibition of p53 expression by 
PAX5 is not of importance in ependymomas. The nega-
tive regulation of p53 by p14ARF is recently suggested to 
be of importance in subgroups of ependymomas. p14ARF 
is located on chromosome 9p21 together with two other 
tumor suppressor genes, p15INK4B and p16INK4A, which 
are all cell cycle regulators.91 Expression of these genes 
is decreased by homozygous deletion, promoter hyper-
methylation, or point mutations in several malignancies. 
In ependymomas, decreased levels of p14ARF protein cor-
relate with increased tumor grade and p53 protein accu-
mulation.92 Deletion of the p16INK4A/p14ARF locus has 
recently been associated with supratentorial ependymo-
mas (Table 2). The observed frequency of inactivation by 
hypermethylation of the three tumor suppressor genes in 
ependymomas is variable (Table 2) and is observed more 
frequently in adults than in children.
Gene Expression and Clinical Characteristics. 
Although recent gene expression profiling studies from 
our and other laboratories have correlated sets of genes 
to patient characteristics, tumor location, and tumor 
grade, the significance of these genes in the pathogen-
esis of ependymomas still needs to be determined. Genes 
that are overexpressed in ependymomas compared with 
normal control tissue include GLU, RAF1, SOX9, cal-
cyphosine, annexin A1, and YAP1. We have shown 
that SOX9 expression was associated with a favorable 
outcome in pediatric ependymomas (Table 2). Several 
genes are characteristic for tumor location. Intracranial 
ependymomas are characterized by the overexpression 
of EMX2, MSI2, ABCG1, FLT1, TOP2A, CRIM1, 
CAMK2D, TFPI2, EBI2, ACTR3, NRCAM, PAX3, 
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NET1, and MSX1, in which the first three were specifi-
cally up-regulated in supratentorial ependymomas and 
the last three in infratentorial ependymomas. ADAM9, 
TFAM, EDN1, and GAS2L1 were down-regulated in 
intracranial ependymomas. HOX genes might play a role 
in the maintenance of the cancer stem-cell phenotype in 
spinal ependymomas, because HOX family members, 
such as HOXB5 and HOXA9, are predominantly over-
expressed in spinal ependymomas.83
Underexpression of proapoptotic nuclear factor-b2 
(NF-b2) and pleckstrin and the overexpression of 
a PTEN homologue are associated with tumor recur-
rence.93 Several genes, such as NRCAM, COL4A2, 
CDK4, and survivin, are overexpressed in ependymo-
mas with high proliferation indices.94,95 Tumor prolif-
eration, reflected by Ki-67 positivity, is an important 
factor in the discrimination between low- and high-
grade ependymoma and is a more reliable unfavorable 
prognostic factor than is histological grading.96
Cytogenetics. As is described for medulloblastomas, 
advanced cytogenetic techniques now allow more pre-
cise determination of chromosomal breakpoint regions 
and the identification of the genes involved. Table 2 and 
Fig. 2 provide the identified balanced translocations and 
a summary of observed copy number aberrations in 
ependymomas, respectively.
Recurrent Copy Number Abnormalities. Frequently 
observed copy number abnormalities in ependymomas 
are losses of 6, 9p, 10, 11, 13, 17, and 22 and gains of 
1q, 5, 7, 9, and 12. Gain of 1q, for example, occurs more 
frequently in children than in adults, correlating with an 
intracranial tumor localization and grade III ependymo-
mas.97,98 More specified regions on chromosomes 1q, 
1q21.1–32.1, and 1q25 are associated with unfavor-
able outcome.98,99 As in medulloblastoma, the 5p15.3 
region, containing the hTERT gene, is frequently gained 
in ependymomas, and high hTERT expression is associ-
ated with proliferation and unfavorable outcome (Table 
2). Loss of 6q is associated with intracranial, predomi-
nantly infratentorial, tumors.100 Gain of chromosome 7 
is predominantly found in spinal cord tumors,97,100 and 
gain or high-level amplification of epidermal growth 
factor receptor (EGFR) at 7p11.2 also predicts progno-
sis in intracranial tumors.98 Another region of gain on 
7p21 contains the candidate proto-oncogenes TWIST1 
and HDAC9,88 and a small region on 7q34 contains the 
ARHGEF5 gene.98 Gain of chromosome 12q and loss 
of chromosome 13 are predominantly observed in intra-
cranial ependymomas.97,98 HOXC4 and CDK4 on 12q13 
are mentioned as genes important in the 12q gain.98,100 
Loss of 17p13.3 is associated with intracranial infraten-
torial ependymomas.88 HIC1 on 17p13.3 is suggested as 
the potentially involved oncogene. In addition to chro-
mosomal loss, HIC1 hypermethylation and consequent 
transcriptional repression are observed in a substantial 
percentage of ependymomas (Table 2), suggesting an 
important role in ependymoma development.
Chromosome 22. Monosomy 22 is found more frequently 
in adults than in children, which results from the higher 
incidence of spinal tumors in adults than in children. 
The existence of ependymomas with loss of 22q lack-
ing NF2 mutations suggests that other tumor suppressor 
genes are located on this chromosome. Multiple regions 
have been suggested, such as 22pter–22q11.2101,102 dis-
tal to the hSNF5/INI1 locus or 22q13.3, including the 
SULT4A1 gene (Table 2). Mutations in hSNF5/INI1 
are rare or absent in ependymomas.103 Gene expression 
profiling of ependymomas has revealed several under-
expressed genes on 22q12.3–q13.3, for example, FBX, 
c22orf2, CBX7, and SBF1.87 Interestingly, CBX7 is 
involved in gene silencing of, for example, the p16INK4A/
p14ARF locus (Table 2).
Epigenetics. Epigenetic studies have also identified genes 
potentially important in ependymoma pathogenesis 
(Table 2). Independent of clinical and histological sub-
type, RASSF1A is transcriptionally silenced by methy-
lation in most ependymomas, suggesting a function as 
a tumor suppressor gene. The fact that methylation is 
almost 100% at every CpG site suggests that RASSF1A 
inactivation is an early event in tumorigenesis. CASP8, 
TFRSF10C, and TFRSF10D are genes involved in the 
TRAIL apoptosis pathway, and methylation of CASP8 
is suggested to be characteristic of low-grade myxopapil-
lary ependymomas. MGMT is involved in DNA repair, 
and silencing of the gene is associated with increased 
sensitivity to alkylating agents in gliomas.104
Conclusion and Future Directions
Much progress has been made in the identification of 
biological factors involved in the pathogenesis of pedi-
atric medulloblastomas and ependymomas in the past 
years, but much has yet to be discovered. Deregulation 
of signaling pathways involved in brain development 
seems to play a more important role in the pathogenesis 
of these tumors than do abnormalities in well-known 
tumor oncogenes and tumor suppressors, such as p53 or 
EGFR. Large collaborative studies are needed to provide 
insights into the importance of the genes discovered so 
far, in order to evaluate their possible use for improved 
risk stratification of patients and their use as therapeutic 
targets. In addition, data from newly developed tech-
niques such as microRNA profiling and the use of single 
nucleotide polymorphisms or exon arrays may provide 
new insights into the regulation of posttranscriptional 
gene expression and alternative splicing.
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